Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapyManagement guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy, Published online: 06 August 2018; doi:10.1038/s41571-018-0075-2Chimeric antigen receptor (CAR) T cell therapies have impressive activity in the treatment of cancer but are associated with potentially fatal toxicities. In light of the approval of CAR T cell therapy for paediatric patients, a panel of experts from the Hematopoietic Stem Cell Transplantation (HSCT) Subgroup of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, the CAR T Cell Therapy-Associated Toxicity (CARTOX) Program at The University of Texas MD Anderson Cancer Center, and several other institutions have developed consensus guidelines for the use and management of these treatments in paediatric patients, which are presented herein.

Source: Nature Reviews Clinical Oncology - August 6, 2018 Category: Cancer & Oncology Authors: Kris M. Mahadeo Sajad J. Khazal Hisham Abdel-Azim Julie C. Fitzgerald Agne Taraseviciute Catherine M. Bollard Priti Tewari Christine Duncan Chani Traube David McCall Marie E. Steiner Ira M. Cheifetz Leslie E. Lehmann Rodrigo Mejia John M. Slopis Rajinder Source Type: research